세계의 잠복성 결핵 진단 시장 : 분석별, 리스크 인자별, 실험실/장소별 - 시장 분석과 예측(2025-2029년), 주요 컨설턴트 가이드 포함

Report Overview:

Latent TB Diagnostics was the province of a few established companies producing a commodity product. No longer. New technologies. New niche markets.

TB Diagnostics is growing, and in some segments the growth is dramatic. Find out who the new leaders are and what areas are most lucrative. What are the basics of competition?

The report forecasts the market size out five years. Some players have already made their mark but disruptive diagnostic technology could change the playing field. Learn about this market including the issues and outlooks.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

Table of Contents

1. Market Guides

• 1.1. Situation Analysis
• 1.2. Guide for Executives and Marketing Staff
• 1.3. Guide for Investment Analysts and Management Consultants

2. Introduction and Market Definition

• 2.1. An Overview of TB Diagnostics
  • 2.1.1. The New Antigen Based TBST
• 2.2. Market Definition
  • 2.2.1. Market Size
  • 2.2.2. Currency
  • 2.2.3. Years
  • 2.2.4. Limitations
• 2.3. Methodology
  • 2.3.1. Methodology
  • 2.3.2. Sources
  • 2.3.3. Authors
• 2.4. Healthcare and the IVD Industry
  • 2.4.1. Global Healthcare Spending
  • 2.4.2. Spending on Diagnostics
  • 2.4.3. Important Role of Insurance for Diagnostics

3. Tuberculosis - Current Science

• 3.1. What is Tuberculosis?
  • 3.1.1. Causes
  • 3.1.2. Pathogenesis
  • 3.1.3. Prevention
  • 3.1.4. Treatment
• 3.2. Diagnosis
  • 3.2.1. Active TB
  • 3.2.2. Latent TB
• 3.3. Prevalence
  • 3.3.1. Impact of COVID on TB Prevalence

4. Industry Overview

• 4.1. Players in a Dynamic Market
  • 4.1.1. Academic Research Lab
  • 4.1.2. Diagnostic Test Developer
  • 4.1.3. Pharmaceutical/Reagent Supplier
  • 4.1.4. Independent Testing Lab
  • 4.1.5. Public National/regional lab
  • 4.1.6. Hospital lab
  • 4.1.7. Physician Lab
  • 4.1.8. Audit Body
  • 4.1.9. Certification Body

5. Market Trends

• 5.1. Factors Driving Growth
  • 5.1.1. Increasing Prevalence
  • 5.1.2. Increasing Diagnostic Options
  • 5.1.3. The Aging World
  • 5.1.4. Increased Health Care Spending
• 5.2. Factors Limiting Growth
  • 5.2.1. The Cost Curve Shrinks the Market
  • 5.2.2. The Diagnostics Dillemma
  • 5.2.3. Adoption Lag and Cost Control
• 5.3. Diagnostic Technology Development
  • 5.3.1. The Multiplex Opportunity
  • 5.3.2. Shifting Role of Physicians in Diagnosis
  • 5.3.3. Diagnostics Moves Out of the Lab
  • 5.3.4. Rapid Testing Changing Medical Practice
  • 5.3.5. The Next Five Years

6. TB Diagnostics - Recent Developments

• 6.1. Recent Developments - Importance and How to Use This Section
  • 6.1.1. Importance of These Developments
  • 6.1.2. How to Use This Section
• 6.2. Danaher, Cepheid Urged to Further Reduce Price of TB Tests
• 6.3. Co-Diagnostics Submits At-Home PCR System
• 6.4. Iinnovation in TB research by Nanopore
• 6.5. New skin test for latent TB diagnostics
• 6.6. Latent TB Infection Screening Recommended
• 6.7. QIAGEN's QuantiFERON-TB Gold Plus gains new CE-marking
• 6.8. PerkinElmer Hopes to Gain Market Share against Qiagen
• 6.9. PBD Biotech to Develop TB Blood Test
• 6.10. WHO Expands Assessment for TB MDx Developers
• 6.11. Cepheid Omni POC System Falls Off Radar
• 6.12. Non-Sputum CRISPR-Based TB Test Shows High Sensitivity
• 6.13. NGeneBio Gets CE Mark for NGS-Based TB Assay
• 6.14. MDx TB Assay From PBD Biotech Shows Promise
• 6.15. Minute Molecular Dx to Launch Rapid PCR Test
• 6.16. Qiagen Next-Gen TB Test Gains Chinese Approval
• 6.17. FIND Invests $21M to Launch POC MDx Platforms
• 6.18. Qiagen, DiaSorin Obtain FDA Approval for Latent TB Test
• 6.19. Oxford Immunotec to Automate Latent TB Test
• 6.20. LumiraDx Eyes Test Menu Expansion
• 6.21. BioMerieux Targeting Hospitals With Desktop Latent TB Test

7. Profiles of Key Companies

• 7.1. AID GmbH
• 7.2. Beijing Wantai
• 7.3. bioMerieux Diagnostics
• 7.4. Boditech Med, Inc
• 7.5. Endo International
• 7.6. Erythra
• 7.7. Generium
• 7.8. Glory Biotechnologies Corp.
• 7.9. Lionex Diagnostics & Therapeutics GmbH
• 7.10. Oxford Immunotec (Perkin Elmer)
• 7.11. Perkin Elmer
• 7.12. Qiagen
• 7.13. R-Biopharm AG
• 7.14. Sanofi
• 7.15. SD Biosensor
• 7.16. Serum Institute of India
• 7.17. Statens Serum Institut
• 7.18. Zhifei Longcom

8. Latent TB Global Diagnostic Markets Overview

• 8.1. Latent TB Diagnostics - Global Market Overview by Country
  • 8.1.1. Table - Global Market by Country
  • 8.1.2. Chart - Global Market by Country
• 8.2. Global Latent TB Diagnostics Markets Overview by Assay
  • 8.2.1. Table - Global Market by Assay
  • 8.2.2. Chart - Global Market by Assay - Segments Growth
  • 8.2.3. Chart - Global Market by Assay - Share by Year
  • 8.2.4. Chart - Global Market by Assay
  • 8.2.5. Chart - Global Market by Assay - Base Year
  • 8.2.6. Chart - Global Market by Assay - Final Year
• 8.3. Global Latent TB Diagnostics Markets Overview by Risk Factor
  • 8.3.1. Table - Global Market by Risk Factor
  • 8.3.2. Chart - Global Market by Risk Factor - Segments Growth
  • 8.3.3. Chart - Global Market by Risk Factor - Share by Year
  • 8.3.4. Chart - Global Market by Risk Factor
  • 8.3.5. Chart - Global Market by Risk Factor - Base Year
  • 8.3.6. Chart - Global Market by Risk Factor - Final Year
• 8.4. Global Latent TB Diagnostics Markets Overview by Lab
  • 8.4.1. Table - Global Market by Lab
  • 8.4.2. Chart - Global Market by Lab - Segments Growth
  • 8.4.3. Chart - Global Market by Lab - Share by Year
  • 8.4.4. Chart - Global Market by Lab
  • 8.4.5. Chart - Global Market by Lab - Base Year
  • 8.4.6. Chart - Global Market by Lab - Final Year

9. Latent TB Diagnostic Market - by Assay

• 9.1. Latent TB Diagnostic - TST
  • 9.1.1. Table Latent TB Diagnostic TST - by Country
  • 9.1.2. Chart - Latent TB Diagnostic TST Growth
• 9.2. Latent TB Diagnostic - IGRA
  • 9.2.1. Table Latent TB Diagnostic IGRA - by Country
  • 9.2.2. Chart - Latent TB Diagnostic IGRA Growth
• 9.3. Latent TB Diagnostic - TBST
  • 9.3.1. Table Latent TB Diagnostic TBST - by Country
  • 9.3.2. Chart - Latent TB Diagnostic - TBST Growth
• 9.4. Latent TB Diagnostic -Other
  • 9.4.1. Table Latent TB Diagnostic Other - by Country
  • 9.4.2. Chart - Latent TB Diagnostic - Other Growth

10. Global Latent TB Diagnostics Markets - By Risk Factor

• 10.1. Latent TB Diagnostic - HIV
  • 10.1.1. Table Latent TB Diagnostic HIV - by Country
  • 10.1.2. Chart - Latent TB Diagnostic HIV Growth
• 10.2. Latent TB Diagnostic - Pediatric
  • 10.2.1. Table Latent TB Diagnostic Pediatric- by Country
  • 10.2.2. Chart - Latent TB Diagnostic Pediatric
• 10.3. Latent TB Diagnostic - Diabetes
  • 10.3.1. Table Latent TB Diagnostic Diabetes - by Country
  • 10.3.2. Chart - Latent TB Diagnostic - Diabetes Growth
• 10.4. Latent TB Diagnostic - Immigration
  • 10.4.1. Table Latent TB Diagnostic Immigration - by Country
  • 10.4.2. Chart - Latent TB Diagnostic - Immigration Growth
• 10.5. Latent TB Diagnostic - Other Risk Factor
  • 10.5.1. Table Latent TB Diagnostic Other Risk Factor - by Country
  • 10.5.2. Chart - Latent TB Diagnostic - Other Risk Factor Growth

11. Global Latent TB Diagnostics Markets - By Lab/Place

• 11.1. Latent TB Diagnostic - Hospital Lab
  • 11.1.1. Table Latent TB Diagnostic Hospital Lab - by Country
  • 11.1.2. Chart - Latent TB Diagnostic Hospital Lab Growth
• 11.2. Latent TB Diagnostic - Outpatient Lab
  • 11.2.1. Table Latent TB Diagnostic Outpatient Lab - by Country
  • 11.2.2. Chart - Latent TB Diagnostic Outpatient Lab Growth
• 11.3. Latent TB Diagnostic - Point of Care
  • 11.3.1. Table Latent TB Diagnostic Point of Care - by Country
  • 11.3.2. Chart - Latent TB Diagnostic Point of Care
• 11.4. Latent TB Diagnostic - Other Place
  • 11.4.1. Table Latent TB Diagnostic Other Place - by Country
  • 11.4.2. Chart - Latent TB Diagnostic Other Place

12. Appendices

• 12.1. United States Medicare System: Clinical Laboratory Fees Schedule